Table 1_Decreased neuronal excitability in hypertriglyceridemia hamsters with acute seizures.docx by Qiuyue Shen (20373266)

“…</p>Conclusion<p>Hypertriglyceridemic Apoc2^−/− hamsters exhibited reduced seizure frequency and decreased cortical neuron excitability. The upregulation of ZDHHC14, leading to increased I_A, may be a crucial mechanism underlying the observed seizure protection.…”

Effect of busulfan treatment on vimentin, a supporting cytoskeletal protein. by Lingjun Zhao (21763122)

Structure of a trial. by Marcel F. Hinss (14675457)

“…While learning effects may have negated the impact of mental fatigue across the 5 experimental blocks, a significant decrease in performance was observed within blocks. …”

siRNA-mediated knockdown of myosin-9 decreases reovirus infection and egress. by Isabel Fernández de Castro (22431012)

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice. by Yu Sang Choi (22656230)

Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. by Shaylah McCool (20818280)

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant reduction in colony-forming ability was observed in U87MG cells treated with 100ΜM SHG-44 compared to 100ΜM cis-platin and the untreated control. …”

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: